The trajectory of companies tied to the drug's legacy presents a complex investment picture . While the initial surge generated substantial returns , generic copies have significantly diminished revenue. Investing in connected pharmaceutical companies now requires a discerning assessment of patent rights , evolving medical trends , and the possibil